Janssen CarePath provides injection support resources that may assist you and your patients.
TREMFYA® Injection Training Support Program
The TREMFYA® Injection Training Support Program provides patients with additional training support to continue their TREMFYA® treatment with confidence.
How the Program works:
- The self-injection training is conducted live by a Registered Nurse, either in-person or over the phone*
- Your patient can only enroll once you, their healthcare provider, and your patient have confirmed that initial self-injection training has been completed in your office
- This program is intended as patient education to reinforce proper injection technique
To have your patients enroll in the TREMFYA® Injection Training Support Program, they must first fill out a program enrollment form, which you can provide after they have met the program eligibility requirements.
The TREMFYA® Injection Training Support Program is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.
*In-person live training may not be available in all areas.
A Nurse is Just a Phone Call Away
Even after you’ve trained your patients to give themselves an injection of TREMFYA®, they may still have questions. Janssen Nurse Support* can help answer their questions about giving themselves an injection at home, preparing their injection site prior to self-injecting, and properly disposing of their used syringe.
Connect your patients with Janssen Nurse Support at 877-CarePath (877-227-3728), available Monday – Friday, 9:00 AM – 8:00 PM ET. At all other times, a nurse will typically return their call in 15 minutes.
*Nurse Support is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.
TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.
WARNINGS AND PRECAUTIONS
TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.
Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.
Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.